(Q37766549)

22 August 2017

1 reference

title

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer (English)

1 reference

22 August 2017

0 references

1 reference

Helena R Chang

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

116

1 reference

22 August 2017

issue

12

1 reference

22 August 2017

page(s)

2856-2867

1 reference

Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Primary systemic therapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Axillary lymph node count is lower after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Trastuzumab in inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25120

7 January 2021

Identifiers

DOI

10.1002/CNCR.25120

1 reference

22 August 2017

1 reference